This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

F573

Immune Pharmaceuticals Ltd.

Drug Names(s): EP1013, F1013

Description: F573 is a di-peptide small-molecule compound with a potent inhibitory effect on caspases, a class of enzymes involved in cell death and inflammation.

Deal Structure: Epicept and GNI
In July 2008, GNI and EpiCept reached an agreement to develop EP1013 in Asia, Australia, and New Zealand, for late-stage viral infection-induced hepatitis. In return for granting a license to GNI to develop EP1013, EpiCept earned an upfront license fee and will be eligible to earn milestone payments and royalties on commercial sales.

EpiCept and Immune
In November 2012, Immune Pharmaceuticals and EpiCept announced that they have entered into a definitive merger agreement. The combined company is to be named Immune Pharmaceuticals. In August 2013, Immune announced the completion of the merger of Immune Pharmaceuticals and EpiCept.

Partners: GNI Group, Ltd.


F573 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug